

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILI	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,288	10/634,288 08/05/2003		Patrick Michael O'Brien	PC25268A	8930
28880	7590	08/25/2005		EXAMINER	
WARNER- 2800 PLYM		T COMPANY	BALASUBRAMANIAN, VENKATARAMAN		
ANN ARBOR, MI 48105				ART UNIT	PAPER NUMBER
	•			1624	

DATE MAILED: 08/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	W/					
		Application No.	Applicant(s)			
	·	10/634,288	O'BRIEN, PATRICK MICHAEL			
	Office Action Summary	Examiner	Art Unit			
		Venkataraman Balasubramanian	1624			
	The MAILING DATE of this communication app		correspondence address			
eriod fo	or Reply		•			
THE - External after - If the - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. e period for reply specified above is less than thirty (30) days, a reply o period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on					
/	•	– action is non-final.				
3)□	Since this application is in condition for allowar	pplication is in condition for allowance except for formal matters, prosecution as to the merits is				
	closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Dispositi	ion of Claims					
4)⊠	Claim(s) 1-16 is/are pending in the application.					
	4a) Of the above claim(s) is/are withdraw					
5)	Claim(s) is/are allowed.					
6)□	Claim(s) is/are rejected.					
7)	Claim(s) is/are objected to.					
8)⊠	Claim(s) <u>1-16</u> are subject to restriction and/or e	election requirement.				
pplicati	ion Papers					
9)	The specification is objected to by the Examine	r.				
10)	The drawing(s) filed on is/are: a)☐ acce	epted or b) \square objected to by the \square	Examiner.			
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
—	Replacement drawing sheet(s) including the correct		- •			
11)	The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
riority ι	under 35 U.S.C. § 119					
_	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau	s have been received. s have been received in Applicati rity documents have been receive	on No			
* 8	See the attached detailed Office action for a list		ed.			
			•			
uttachmen	t(s)					
) 🔲 Notic	e of References Cited (PTO-892)	4) Interview Summary				
	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate Patent Application (PTO-152)			
	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	6) Other: .	atent Application (FTO-152)			

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04)

Art Unit: 1624

DETAILED ACTION

Claims 1-16 are pending.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-5, 7 and 9-16 drawn to a compound of formula I, wherein Y¹ is O , namely bicyclooxazinone compound, composition and method of use, classified in class 544, subclasses 105 and others, class 514, subclasses 230.8 and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups. .
- II. Claims 1-5 and 8-16 drawn to a compound of formula I, wherein Y¹ is S, SO, SO₂ namely bicyclothiazinone compound, and composition and method of use, classified in class 544, subclasses 48, 51 and others, class 514, subclasses 224.2 and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups.
- III. Claims 1, 4-6 and 9-16, drawn to a compound of formula I, wherein Y¹ is CH₂, Y⁵, Y⁶ and Y⁸ are nitrogen, namely bicyclotriazine compound, composition and method of use, classified in class 544, subclass 184, class 514, subclasses 243 and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups.
- IV. Claims 1, 4-6 and 9-16, drawn to a compound of formula I, wherein Y¹ is CH₂, Y⁵, Y⁶ are nitrogen and Y⁸ is C(R⁵), namely bicyclopyridazine compound, composition and method of use, classified in class 544,

Art Unit: 1624

subclass 236, class 514, subclass 248 and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups.

- V. Claims 1, 4-6 and 9-16, drawn to a compound of formula I, wherein Y¹ is CH₂, Y⁶, Y⁸ are nitrogen and Y⁵ is C(R⁵), namely bicyclopyrimidine compound, composition and method of use, classified in class 544, subclass 279, class 514, subclass 258 and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups.
- VI. Claims 1, 4-6 and 9-16, drawn to a compound of formula I, wherein Y¹ is CH₂, Y⁵, Y⁸ are nitrogen and Y⁶ is C(R⁵), namely bicyclopyrazine compound, composition and method of use,, classified in class 544, subclass 350, class 514, subclasses 249 and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups.
- VII. Claims 1, 4-6 and 9-16, drawn to a compound of formula I, wherein Y¹ is CH₂, one of Y⁵, Y⁸ and Y⁶ is nitrogen, the other two C(R⁵), or Y⁵, Y⁸ are and Y⁶ are C(R⁵), namely bicyclopyrazine compound, composition and method of use, classified in class 546, subclasses 118, 153, class 514, subclasses 300, 312 and others depending upon the preferred embodiments of other heterocyclic or heteroaryl groups..

The inventions are distinct, each from the other because of the following reasons:

As per MPEP § 803, there are two criteria for a proper requirement for restriction between patentably distinct inventions:

(A) The inventions must be independent or distinct as claimed and

(B) There must be a serious burden on the examiner if restriction is required.

Invention I, II, III, IV, V, VI and VII are independent and distinct from each other because they are directed to structurally dissimilar compounds with distinct Y¹, Y⁵, Y⁶ Y⁸ choices that lack common core, namely, bicyclothiazinone versus bicyclopyridazine bicvclooxazinone bicyclotriazine versus versus versus bicyclopyrimidine versus bicyclopyrazine versus bicyclopyridinone core compounds. Consequently, the groups have different classifications and require separate prior art searches. They can be made and used independently. Art which may render obvious or anticipate one of the groups would not necessarily do the same for the other group. For example prior art cited in the Information Disclosure Statement may not be applicable to all the above groups. Each can support a patent as the compounds of each group are capable of being utilized alone not in combination with other members listed in the Markush group.

In addition, it is necessary to classify and search all the controlling cores generically embraced in Group I, II, III, IV, V, VI and VII along with various choices of heterocyclic ring embraced variable groups. Such a search of all controlling cores would serious search burden.

This application contains claims directed to the following patentably distinct species of the claimed invention with variety of Y¹, Y⁵, Y⁶ and Y⁸ substituents. See claims 10 and 11

Art Unit: 1624

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-9 and 12-16 are generic.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1624

In view of distinct nature of each of the invention, the restriction is set forth in writing.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication from the examiner should be addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (571) 272-0662. The examiner can normally be reached on Monday through Thursday from 8.00 AM to 6.00 PM. The Acting Supervisory Patent Examiner (SPE) of the art unit 1624 is James O. Wilson, whose telephone number is (571) 272-0661.

The fax phone number for the organization where this application or proceeding is assigned (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published

Art Unit: 1624

applications may be obtained from either Private PAIR or Public PAG. Status

Page 7

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business

Center (EBC) at 866-2 17-9197 (toll-free).

Venkataraman Balasubramanian

8/23/2005